The coronavirus disease 2019 (COVID-19) pandemic will present an unprecedented stressor to patients and health care systems across the globe. Because there is currently no vaccine or treatment for the underlying infection, current health efforts are focused on providing prevention and screening, maintaining continuity of treatment for other chronic conditions, and ensuring access to appropriately intensive

The idea that we can reduce the incidence of psychotic disorders through detection and intervention in the prodromal stage of illness has generated increasing enthusiasm and research over the past 2 decades. This work has sought largely to identify individual-level changes in subjective experience, functioning, or brain volume or activity that immediately precede acute symptom onset. However, mental

Mission Statement: JAMA Psychiatry strives to publish original, state-of-the-art studies and commentaries of general interest to clinicians, scholars, and research scientists in psychiatry, mental health, behavioral science, and allied fields. The journal seeks to inform and to educate its readers as well as to stimulate debate and further exploration into the nature, causes, treatment, and public

In the Original Investigation titled “Risk of Subjection to Violence and Perpetration of Violence in Persons With Psychiatric Disorders in Sweden,”1 published online January 15, 2020, there was an error in the Abstract Results. The estimate given in line 5 as 7.5 [95% CI, 7.4-7.6] should have been 1.0 [95% CI, 0.9-1.0] and the estimate given in line 6 as 1.0 [95% CI, 0.9-1.0] should have been 7.5 [95%

In the Original Investigation titled “Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial” by Correll et al,1 published online January 8, 2020, in the Efficacy subsection of the Results section, the multiplicity-adjusted P values for change from baseline to day 28 in the Positive and Negative Syndrome Scale total score vs placebo and for change from baseline

In Reply In our study,1 we used 3 waves of data from the longitudinal Population Assessment of Tobacco and Health study to show that adolescents who report more frequent social media use report greater symptoms of psychopathology 1 year later. In their letter, Keyes and Kreski replicated our findings. They then showed that, after further adjusting for psychopathology measured concurrently with social

To the Editor Riehm et al1 report an association between social media use and increased risk of internalizing and combined internalizing/externalizing problems 1 year later (between waves 2 and 3 of Population Assessment of Tobacco and Health study data), controlling for psychopathology and alcohol/marijuana use at wave 1. However, the analytic strategy is vulnerable to substantial residual confounding

Medication selection in depression still relies primarily on trial and error, frustrating both patients and clinicians. Diagnostic tests that predict treatment response in advance could facilitate an informed approach and reduce suffering. Ideally, those tests would directly measure brain function. The primary research test of brain function, functional magnetic resonance imaging (fMRI), is too expensive

Evidence has accumulated over the last 40 years indicating increased rates of violent perpetration and being the target of violence among people with mental illness. Landmark data collected in the early 1980s by the Epidemiologic Catchment Area study found a 12-month prevalence of 12% for any type of violence among people with mental disorders, which dropped to 7% if people with comorbid substance

Antipsychotic medications are the primary pharmacologic treatment for schizophrenia and were initially discovered fortuitously in the early 1950s. Chlorpromazine was the prototype of this class of medications, retroactively noted as first-generation antipsychotics, which are primarily characterized by their high-affinity antagonism at the dopamine D2 receptor. The rediscovery of clozapine in 1989 heralded

Cannabidiol (CBD), a phytocannabinoid with potential medicinal properties, has recently hit all levels of society with tidal wave force that very few saw coming. After being virtually unknown by most people not even a decade ago, CBD is now in the general lexicon with numerous companies riding the CBD wave: more than 1000 products are being sold through the internet, dispensaries, pharmacies, large

In early 2019, representatives of the US Department of Justice sued to prevent a nonprofit group from opening a supervised consumption facility in Philadelphia, Pennsylvania. This case, United States v Safehouse, has drawn considerable attention given its implications for US drug policies; however, one exchange during an August 2019 hearing was particularly disconcerting. After Safehouse president

US veterans face severe mental health needs; there have been more than 6000 suicides annually from 2008 to 2016, a 25.9% jump in suicides from 2005 to 2016, a suicide rate 1.5-fold higher than nonveterans, and higher suicide rates for veterans accessing Department of Veterans Affairs (VA) facilities vs those not using VA services, veterans overall, and nonveterans.1 On June 6, 2018, the Veterans Affairs

Rick Antony Adams Jean Addington Esben Agerbo

The Danish nationwide study by Dalsgaard and colleagues1 in this issue of JAMA Psychiatry confirms previous studies of smaller scope: mental disorders with an onset during childhood are associated with substantial underachievement in school. The Danish study stands out for its simultaneous evaluation of 29 mental disorders in 629 622 youths. It shows that adolescents with a prior mental disorder have

In the Original Investigation titled “Outcomes of Online Mindfulness-Based Cognitive Therapy for Patients With Residual Depressive Symptoms: A Randomized Clinical Trial,”1 published online January 29, 2020, in the Conflict of Interest Disclosures, Dr Segal and Dr Dimidjian added that they are cofounders of Mindful Noggin, Inc. In the Additional Contributions, the NogginLabs team was added as helping

Depression is a serious and common mental health problem. Although a number of psychological and pharmacological treatments are available for this serious psychiatric condition, there is still a lot of room for improvement. As is true for virtually all mental disorders, the most common and comparatively most effective form of psychological treatment for depression is cognitive behavioral therapy (CBT)

In 2017, there were 47 173 suicides in the US.1 The Surgeon General’s 2012 National Strategy for Suicide Prevention2 articulated strategies for addressing this epidemic, which included increased access to psychiatric services, restricting access to lethal means, and increasing resources for suicide prevention research, including proposed harmonized coding and methods to improve suicide-related data

Three decades ago, the schizophrenia field finally began to challenge the intrinsic pessimism that had inhibited preventive approaches for a century. Early detection and specialized early treatment models for first-episode psychosis have since become the global standard of care, producing better outcomes that “bend the curve” of the early course of illness1 and have opened the door to the prevention

The evaluation and success of our efforts to prevent, detect, and treat mental illness depend on the assessment of psychopathology. Almost all psychiatric assessments consist of asking questions, through questionnaires or interviews, about behaviors and experiences. We either ask the person being assessed or someone who knows them well. Based on the answers, we diagnose, recommend treatment, and monitor

In the Clinical Challenge, “Treatment of First-Episode Schizophrenia in a Young Woman,”1 published online October 30, 2019, there was an error in a quiz answer choice. Answer A was corrected to “Consider the risk of adverse events and which drugs are approved for use” instead of “Commence treatment with oral amisulpride.” In addition, the Discussion and Patient Outcome sections have been corrected

In the Original Investigation titled “Association of Maternal Eating Disorders With Pregnancy and Neonatal Outcomes,”1 published online November 20, 2019, the surname of the second author was inaccurate. Angelica Lindén Hirschberg should be referred to as Dr Hirschberg, not Dr Lindén Hirschberg. The error has been corrected.

In the Original Investigation titled “Prevention of Recurrence After Recovery From a Major Depressive Episode With Antidepressant Medication Alone or in Combination With Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial,”1 published online December 4, 2019, there was an error in the length of curve lines depicted in Figure 2. For panel A and panel B, the line labeled Withdrawn

In Reply We thank Mueser and McGurk for the interest in this Danish randomized clinical trial investigating the effects of individual placement and support (IPS) and IPS supplemented with cognitive remediation and social skills training among 720 participants with severe mental illness.1 First, the authors state that the rates of competitive employment are low compared with previous IPS trials. This

To the Editor We would like to point out several limitations of the study by Christensen et al1 comparing the effects of the individual placement and support (IPS) model of supported employment with IPS enhanced by cognitive remediation and social skills training (IPSE) and service as usual on work in persons with severe mental illness that preclude drawing firm conclusions about the potential benefits

In Reply We thank King and Ehrlich for their thoughtful Letter critiquing our meta-analysis1 that examined delay discounting as a transdiagnostic process in psychiatric disorders. In our article, we proposed that delay discounting, an index of impulsive decision-making, falls on a continuum. At the aggregate level, most disorders examined (eg, major depressive disorder, bipolar disorder, schizophrenia

To the Editor Amlung and colleagues1 published a meta-analysis of delay discounting (DD), a behavioral measure of impulsivity and self-control, including 57 effect sizes from 43 studies across 8 psychiatric diagnostic categories. Results indicated a greater preference for smaller immediate monetary rewards (ie, more impulsive decision-making) in 6 conditions (major depression, schizophrenia, bipolar